medigraphic.com

2010, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (3)

Cost-effectiveness of anxiolytics in anxiety disorders

Constantino-Casas P, León-González G, Nevárez-Sida A, Valencia-Huarte E, García-Contreras F

Language: Spanish
References: 21
Page: 303-308
PDF size: 50.26 Kb.


ABSTRACT

Background: adequate treatment of anxiety disorders reduces the economic impact, improves functionality in daily life activities and quality of life. Pharmacologic treatment depends on patient’s characteristics and doctor’s experience. The aim of this study was to determine the use of resources in anxiety disorder and to analyze its cost-effectiveness.
Methods: use of resources related to chronic treatment of anxiety disorders and cost-effectiveness of drugs were determined, as well as patients’ out-ofpocket expenses and productivity loss. A one-year time horizon and decision tree with benzodiazepines, selective inhibitor of serotonin re-intake (SISR) and tricyclic antidepressant drugs were included.
Results: benzodiazepines were the treatment that had the lowest total cost ($147 587 MXP), followed by SISR (incremental cost of $2 182 MXP), and the highest cost was tricyclic antidepressant drugs ($155 903 MXP).
Conclusions: benzodiazepines are good alternative for anxiety disorder because of their high effectiveness to control symptoms and because they reduce hospital costs.


REFERENCES

  1. Organización Mundial de la Salud/Organización Panamericana de la Salud. CIE-10 Clasificación Estadística Internacional de Enfermedades y Problemas Relacionados con la Salud. Washington, D.C.: OMS; 1995.

  2. Spitzer RL, editor. DSM IV. Washington DC: American Psychiatric Press; 1994.

  3. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12 month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005;62(6):617- 627. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847357/

  4. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004;291(21):2581-2590.

  5. Organización Mundial de la Salud. Atlas, recursos de salud mental en el mundo. Ginebra, Suiza: Organización Mundial de la Salud; 2001. Disponible en http://www.who.int/mental_health/media/en/255.pdf

  6. Medina-Mora ME, Borges G, Lara-Muñoz C, Benjet C, Blanco-Jaimes J, Fleiz- Bautista C, et al. Prevalencia de trastornos mentales y uso de servicios: Resultados de la Encuesta Nacional de Epidemiología Psiquiátrica en México. Salud Mental 2003,26(4):1-16.

  7. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50(2):85-94.

  8. DuPont R, DuPont C, Rice D. Costes económicos de los trastornos de ansiedad. En: Stein D, Hollander E, editores. Tratado de los trastornos de ansiedad. Barcelona: Ars Médica; 2004. p. 567-578.

  9. Bobes J, Bousoño M, González M, Sáiz PO. Trastornos de ansiedad y trastornos depresivos en la atención primaria. España: Masson; 2001. p. 61-91.

  10. Menninger WW. Role of the psychiatric hospital in the treatment of mental Illness. En: Sadock B, Sadock V, Kaplan HI, editores. Kaplan and Sadock’s comprehensive textbook of psychiatry. Seventh edition. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 3210-3218.

  11. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12- month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51 (6):8-19.

  12. Menddlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000;157(5): 669-682.

  13. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60(7):427-435.

  14. Amaya-Jackson L, Davidson JR, Hughes DC, Swartz M, Reynolds V, George LK et al. Functional impairment and utilization of services associated with posttraumatic stress in the community. J Trauma Stress 1999;12(4):709-724.

  15. Simon GE, Vonkorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area Study. Am J Psychiatry 1991;148(11):1494- 1500.

  16. Kane FJ Jr, Wittels E, Harper RG. Chest pain and anxiety disorder. Tex Med 1990;86(7):104-110.

  17. Hollander E, Simeon D, Gorman J, Trastornos de ansiedad. En: Hales R, Yudofsky S, Talbot J, editores. Tratado de psiquiatría DSM IV. Tercera edición. Barcelona: Masson; 2000. p. 563-631.

  18. Heuzenroeder L, Donnelly M, Haby MM, Mihalopoulos C, Rossell R, Carter R, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Australian N Z J Psychiatry 2004; 38(8):602-612.

  19. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev 2004;10(1):45-76.

  20. Sheehan DV. The management of panic disorder. J Clin Psychiatry 2002;63 (Suppl 14):17-21.

  21. Guidelines for assesing and treating anxiety disorders. [Monografia en internet]. New Zealand: National Health Committee; 1998. Disponible en http://www.nzgg.org.nz/guidelines/0038/Anxiety_ guideline.pdf




2020     |     www.medigraphic.com